Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Start-Up Archer Preps Alzheimer’s Drugs For Phase I

This article was originally published in The Pink Sheet Daily

Executive Summary

IND filed, company aims to use nilvadipine derivative against soluble amyloid.

You may also be interested in...

The Alzheimer’s Divide: Wyeth Phase II Underscores Key Choice For Sponsors

Wyeth/Elan's Phase II bapineuzumab trial for Alzheimer's disease did not impress investors, but the sponsors are convinced they made the right bet in how they designed the study

Industry Roundtable: Neurotech Execs Discuss Innovation, Challenges, Next Steps

In Part I of a series, panelists discuss outcomes measures in a sector with unique regulatory conditions and the need for biomarkers.

Lilly Makes Big Biologics Play For Alzheimer’s

But study published in Lancet raises questions about efficacy of anti-amyloid therapy.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts